LXRX:NASDAQ
Lexicon Pharmaceuticals Inc
1,82Â US$
0,00%
(0,00) 1K
1,81Â US$
arrow_downward
-0,68% (-0,012)bedtimeYopilgandan keyin
Savdolar yopilgan: 2-okt, 16:00:01 (GMT-4) · USD
search
Barcha belgilar
| Belgi | Narxi | Oʻzgartirishlar | Dinamika (%) |
|---|
insights_autoLXRX tikeri uchun statistika yaratilmoqda...
Ochish
1,85Â US$
Yuqori
1,87Â US$
Past
1,80Â US$
Bozor kapitali
809,82Â mln
Oʻrtacha hajm
3,13Â mln
Hajmi
2,32Â mln
52 haftalik eng yuqori
2,68Â US$
52 haftalik eng past
1,10Â US$
Aksiya boʻyicha daromad
-0,15Â US$
Beta
1,36
Muomaladagi aksiyalar
444,96Â mln
Xodimlar soni
81
Ochish
1,85Â US$
Yuqori
1,87Â US$
Past
1,80Â US$
Bozor kapitali
809,82Â mln
Oʻrtacha hajm
3,13Â mln
Hajmi
2,32Â mln
52 haftalik eng yuqori
2,68Â US$
52 haftalik eng past
1,10Â US$
Aksiya boʻyicha daromad
-0,15Â US$
Beta
1,36
Muomaladagi aksiyalar
444,96Â mln
Xodimlar soni
81
Yangiliklar
Internet manbalari va yangilik hamkorlarimizdan
AD HOC NEWS
·
1 kun oldin
Cantor Fitzgerald targets Lexicon Pharmaceuticals stock at USD 8.00
Seeking Alpha
·
2 kun oldin
Lexicon Pharmaceuticals: Upgrading On Sotagliflozin HCM Data In Q1 '27 And More
Profil
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company developing treatments for human disease. The company was founded in 1995 in The Woodlands, Texas under the name Lexicon Genetics, Incorporated by co-founders Professor Allan Bradley, FRS and Professor Bradley's postdoctoral fellow Arthur T Sands. The company has used its mouse gene knockout technology and in vivo screening capabilities to study nearly 5,000 genes in its Genome5000 program and has identified over 100 potential therapeutic targets. Lexicon has advanced multiple drug candidates into human clinical trials and has a broad and diverse pipeline of drug targets behind its clinical programs. Lexicon is pursuing drug targets in five therapeutic areas including oncology, gastroenterology, immunology, metabolism, and ophthalmology.
The company's clinical drug candidates include sotagliflozin for the treatment of type 2 diabetes; LX1033 for the treatment of irritable bowel syndrome and other gastrointestinal disorders; telotristat ethyl for the treatment of the symptoms associated with carcinoid syndrome; and LX2931 for the treatment of autoimmune diseases, such as rheumatoid arthritis. Wikipedia
Lexicon Pharmaceuticals Inc haqida